- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00753623
Clinical Management of Neuropathic Pain With Ramelteon
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject will be between ages 18 to 65 years.
- Subject has not been on ramelteon for at least one month.
- Subject agrees to make no change in his/her current pain medications during the entire study period (5 weeks). This requirement will ensure that valid comparisons of primary and secondary measures can be made before and after the study.
- Subject has a VAS pain score of 5 or above at the beginning of the study.
- Subject has had a neuropathic pain condition as listed above for at least three months. This requirement is to avoid clinical uncertainty from an unstable pain condition and to minimize the study variation.
- Female subjects of childbearing potential must have a negative urine pregnancy test at the initial visit.
Exclusion Criteria:
- Subject has moderate to severe liver impairment.
- Subject has Liver Function Tests (LFT's) >1.5X normal.
- Subject has a history of renal impairment.
- Subject has moderate or severe cardiac or pulmonary disease including a base line oxygen saturation of less than 95% on room air or any requirement for supplemental oxygen.
- Subject has a history of glaucoma.
- Subject has obstructive sleep apnea.
- Subject is taking medications for sleep disorders including insomnia.
- Subject has a major psychiatric disorder (major depression requiring a recent hospitalization within three months prior to the study; bipolar disorder; schizophrenia; psychotic disorders; substance abuse).
- Subject has a history of dementia or delirium.
- Subject has a history of falls.
- Subject is pregnant or lactating.
- Subject is using an illicit drug detected by a screening test.
- Subject is currently taking Fluvoxamine.
- Subject has been taking Ketoconazole in the past two weeks.
- Subject has known hypersensitivity to ramelteon.
- Subject has pending litigation related to his/her neuropathic pain condition.
- Subject has Concurrent participation in other research drug trials or other study participation within 30 days of enrollment in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Ramelteon first, placebo second
In a crossover design, a subject will be first assigned to the ramelteon arm and then switched over to the placebo arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night.The ramelteon and placebo will be blinded by the central pharmacy. The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long. |
ramelteon (8 mg)
Other Names:
In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
|
Placebo Comparator: Placebo first, ramelteon second
In a crossover design, a subject will be first assigned to the placebo arm and then switched over to the ramelteon arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night. The ramelteon and placebo will be blinded by the central pharmacy. The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long. |
ramelteon (8 mg)
Other Names:
In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in Visual Analog Scale (VAS) for Pain (0-10) Between Treatments
Time Frame: VAS score at baseline and after the treatment period
|
Subjects were asked to rate their pain the VAS with 0 being no pain and 10 being the worst pain they can imagine.
The VAS scores were compared between the baseline and after a period of treatment.
A negative number indicates an improvement in pain from baseline score.
|
VAS score at baseline and after the treatment period
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jianren Mao, M.D., Ph. D., Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2008P-000988
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuropathic Pain
-
University Hospital, Clermont-FerrandFondation ApicilCompletedNeuropathic Traumatic Pain | Pain NRS ≥ 4 | Peripheral Neuropathic Pain | Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4France
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPostherpetic Neuralgia (PHN) | Chemotherapy Induced Neuropathic Pain | Diabetic Peripheral Neuropathic Pain (DPN) | HIV-related Neuropathic Pain (HIV)Colombia, Mexico, Ecuador, Peru, Venezuela
-
University Malaysia SarawakPersatuan Diabetes MalaysiaCompletedNeuropathic Pain, Nociceptive PainMalaysia
-
University Hospital, Strasbourg, FranceTerminatedPostthoracotomy Pain | Postthoracoscopy Neuropathic PainFrance
-
AstraZenecaCompletedNociceptive Pain | Peripheral Neuropathic PainUnited Kingdom
-
University Hospital, Clermont-FerrandRecruitingPeripheral Neuropathic PainFrance
-
Daiichi Sankyo Co., Ltd.CompletedCentral Neuropathic PainJapan, Korea, Republic of, Taiwan
-
Hospices Civils de LyonCompletedPharmacoresistant Neuropathic PainFrance
-
Yuhan CorporationCompletedPeripheral Neuropathic PainKorea, Republic of
-
University Hospital, Clermont-FerrandCompletedNeuropathic Pain RebelFrance
Clinical Trials on Ramelteon
-
Virginia Commonwealth UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
TakedaCompletedChronic Obstructive Pulmonary Disease | COPDUnited States
-
TakedaCompletedSleep Apnea, ObstructiveUnited States
-
Southern Arizona VA Health Care SystemUnknownGastroesophageal Reflux Disease | Chronic InsomniaUnited States
-
Centennial Medical CenterRecruiting
-
University of California, San DiegoActive, not recruitingDelirium | Sleep Deprivation
-
TakedaCompleted
-
Massachusetts General HospitalWithdrawnParkinson's Disease | Sleep Disorders | Dementia With Lewy Bodies | Huntington's Disease | Circadian DysregulationUnited States
-
Charlottesville NeuroscienceTakeda Pharmaceuticals North America, Inc.TerminatedMigraine HeadacheUnited States
-
TakedaCompletedChronic InsomniaUnited States